title: Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis.
abstract: BACKGROUND
  The prescription of fixed-dose combinations (FDC) of antihypertensive drugs has increased rapidly since the relaxation of the prescription-term restriction. In this study, we used the opportunity of this policy change in Japan as an instrument to assess the causal impact of switching to FDC on hypertensive treatment costs.
  
  
  METHODS
  Claims data from 64 community pharmacies located in Tokyo were used to identify hypertensive patients under continuous treatment with angiotensin-receptor blockers (ARBs). Patients switching to FDC between December 2010 and April 2011 were compared to patients who did not receive FDC (control group). Changes in annual antihypertensive drug costs were compared using a difference-in-differences approach to adjust for patient characteristics and use of concomitant medication. Subpopulation analyses were also performed, taking into account pre-index treatment patterns and prescribers' characteristics.
  
  
  RESULTS
  There were 542 patients who switched to FDC and 9664 patients in the control group. No significant differences were observed between the 2 groups, except for antihypertensive drug use patterns before the policy change and prescribers' characteristics. The switch to FDC was associated with an annual saving of 10,420 yen (US$112.0) in antihypertensive drug costs. Approximately 20% of the FDC patients, however, switched from ARB alone, and their drug costs increased by 2376 yen (US$25.5).
  
  
  CONCLUSIONS
  For hypertensive patients who required ARB-based combination therapy, switching to FDC drugs had a significant cost-saving effect. However, the policy change of relaxing the prescription-term restriction could encourage aggressive treatment, i.e., switching to a combination therapy from monotherapy, regardless of medical conditions. Further research is required to evaluate the possible negative aspects of FDC drugs.
authors.affiliation: Meiji Pharmaceutical University, Tokyo, Japan. makazawa@my-pharm.ac.jp
authors.forename: Manabu
authors.initials: M
authors.lastname: Akazawa
authors.forename: Katsushi
authors.initials: K
authors.lastname: Fukuoka
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000191:economics*; D003365:Costs and Cost Analysis; D057915:Drug Substitution / Q000191:economics*; D004359:Drug Therapy, Combination / Q000191:economics; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007345:Insurance Claim Review; D007564:Japan; D008297:Male; D008875:Middle Aged; D010594:Pharmacies; D012189:Retrospective Studies
chemical_list: D000959:Antihypertensive Agents
references.citation: Hypertens Res. 2006 Mar;29(3):143-51
references.pmid: 16755149
references.citation: Curr Med Res Opin. 2010 Dec;26(12):2877-87
references.pmid: 21067459
references.citation: Value Health Reg Issues. 2012 May;1(1):98-104
references.pmid: 29702835
references.citation: Am J Hypertens. 2008 May;21(5):509-13
references.pmid: 18437141
references.citation: J Clin Hypertens (Greenwich). 2011 Dec;13(12):898-909
references.pmid: 22142349
references.citation: Eur Heart J. 2007 Jun;28(12):1462-536
references.pmid: 17562668
references.citation: Curr Med Res Opin. 2008 Sep;24(9):2597-607
references.pmid: 18812017
references.citation: Blood Press. 2008;17(1):7-17
references.pmid: 18568687
references.citation: Value Health. 2010 Sep-Oct;13(6):846-52
references.pmid: 20561344
references.citation: Clin Exp Hypertens. 2011;33(5):309-15
references.pmid: 21649528
references.citation: J Med Econ. 2012;15(1):8-18
references.pmid: 22011107
references.citation: BMC Fam Pract. 2008 Nov 06;9:61
references.pmid: 18990240
references.citation: Ther Adv Cardiovasc Dis. 2013 Feb;7(1):27-39
references.pmid: 23328188
references.citation: J Med Econ. 2011;14(5):576-83
references.pmid: 21728914
references.citation: Can J Clin Pharmacol. 2009 Winter;16(1):e151-5
references.pmid: 19193969
references.citation: Yakugaku Zasshi. 2005 Dec;125(12):959-69
references.pmid: 16327241
references.citation: Manag Care. 2010 Jul;19(7):36-42
references.pmid: 20672530
references.citation: Curr Med Res Opin. 2008 Aug;24(8):2389-401
references.pmid: 18616863
references.citation: Am J Hypertens. 2008 May;21(5):492
references.pmid: 18437138
references.citation: Clin Ther. 2008 Aug;30(8):1558-63
references.pmid: 18803997
references.citation: Hypertension. 2010 Feb;55(2):399-407
references.pmid: 20026768
references.citation: Value Health. 2007 Jan-Feb;10(1):3-12
references.pmid: 17261111
references.citation: Hypertension. 2003 Dec;42(6):1206-52
references.pmid: 14656957
references.citation: Hypertens Res. 2009 Jan;32(1):3-107
references.pmid: 19300436
references.citation: Congest Heart Fail. 2003 Nov-Dec;9(6):324-32
references.pmid: 14688505
references.citation: Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):904-11
references.pmid: 18461632